Daily non-political popular news in brief.

'Tweens' double use of diabetes drugs

11-07-2007 · EurekAlert!

Prescriptions to children with chronic health problems have increased, according to new St. Louis University School of Public Health research.

Keywords: tweens, double, diabetes, drugs, tween, diabete, drug

« Previous | Next »

Similar news on "'Tweens' double use of diabetes drugs":

JCI table of contents: Sept. 4, 2007
09-04-2007 · EurekAlert!
This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published Sept. 4, 2007, in the JCI, including: Immunosuppressive drugs are a double-edged sword to type 1 diabetics; It's a knock out: eIF4E-specific antisense oligonucleotides knock down cancer; New use as an anti-fungal agent for old drug; Antioxidant used in the clinic causes disease in mice; and The beta1-adrenergic receptor is two faced in the heart; and others.
Similar news · Read more »
Hopkins scientists uncover cause of antipsychotic drug weight gain
02-12-2007 · EurekAlert!
Johns Hopkins brain scientists have hit on how and why some powerful drugs used for treating mental illnesses cause patients to gain so much weight that they often develop life-threatening complications such as diabetes and heart disease.
Similar news · Read more »
Diabetes medication and lifestyle changes can help treat weight gain induced by antipsychotic drugs
01-08-2008 · EurekAlert!
Lifestyle intervention and the drug metformin are both effective against antipsychotic-induced weight gain, and treatment is most effective when the two therapies are combined, according to a study in the Jan. 9/16 issue of JAMA.
Similar news · Read more »
Enzyme structure reveals new drug targets for cancer and other diseases
02-14-2008 · EurekAlert!
Researchers now have a clearer understanding of how a key protein controls gene activity and how mutations in the protein may cause disease. The work could provide new avenues to design drugs aimed at cancer, diabetes, HIV, and heart disease.
Similar news · Read more »
Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
12-07-2007 · Brookhaven National Laboratory
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced positive initial top-line results from an investigator-initiated Phase II double-blind, placebo-controlled trial, which demonstrates that vigabatrin is effective for the treatment of cocaine addiction. Catalyst's lead compound, CPP-109, is bioequivalent to vigabatrin.
Similar news · Read more »
Prescribing information for kidney disease far too vague
12-06-2006 · EurekAlert!
Prescribing information for healthcare professionals treating patients with kidney disease is too vague, concludes the latest issue of Drug and Therapeutics Bulletin (DTB). Many of the 4-5 percent of the UK population with serious chronic kidney disease are elderly people, who are often taking several different drugs. Other risk factors for the disease include diabetes and high blood pressure.
Similar news · Read more »
OCT1 required for therapeutic effects of diabetes drug Metformin
05-01-2007 · EurekAlert!
Metformin is among the most widely prescribed drugs for the treatment of type 2 diabetes. Mouse and human studies led by Kathleen Giacomini from the University of California, San Francisco, and reported in the May 1 issue of the JCI indicate that organic cation transporter 1 is important in mediating the therapeutic effects of metformin and that genetic variation in OCT1 in diabetics may contribute to the varied patient responses to this drug.
Similar news · Read more »
Immunosuppressive drugs are a double-edged sword to type 1 diabetics
09-04-2007 · EurekAlert!
Type 1 diabetes occurs when immune cells destroy pancreatic insulin producing beta-cells. It was hoped that islet transplantation would provide a cure for the disease, however, transplant success is short-lived and accompanied by significant side effects. New data indicate that the immunosuppressive drugs used to prevent islet transplant rejection suppress beta-cell regeneration in diabetic mice, raising the possibility that identifying immunosuppressive drugs that do not inhibit beta-cell regeneration might lead to successful regenerative islet transplantation.
Similar news · Read more »
Catalyst Pharmaceutical Partners, Inc. Initiates U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Dependence
07-10-2007 · Brookhaven National Laboratory
Catalyst Pharmaceutical Partners, Inc., a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial of CPP-109 in patients with cocaine dependence. CPP-109, an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release, is Catalyst's lead compound, vig
Similar news · Read more »
Older is better -- Top-10 comparison of diabetes drugs give metformin top grade
07-24-2007 · EurekAlert!
Type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.
Similar news · Read more »